Steven Schuster Represents PixarBio Corporation in Initial Public Offering

On October 31, 2016, PixarBio Corporation completed a public offering through a reverse merger and simultaneously consummated a private placement. PixarBio Corporation is a specialty pharmaceutical company focused on pre-clinical and commercial development of novel non-opiate neurological drug delivery systems for post-operative pain through delivery of non-opiate prescription drugs.